

1 **Inferring Spatially Resolved Transcriptomics Data from Whole Slide Images for the**
2 **Assessment of Colorectal Tumor Metastasis: A Feasibility Study**

3 Michael Fatemi¹, Eric Feng², Cyril Sharma³, Zarif Azher², Tarushii Goel⁴, Ojas Ramwala⁵, Scott
4 Palisoul⁶, Rachael Barney⁶, Laurent Perreard⁷, Fred Kolling⁷, Lucas A. Salas^{8,9,10}, Brock C.
5 Christensen^{8,9,11}, Gregory Tsongalis⁶, Louis Vaickus⁶, Joshua J. Levy^{6,8,12,13,*}

- 6 1. Department of Computer Science, University of Virginia, Charlottesville, VA
- 7 2. Thomas Jefferson High School for Science and Technology, Alexandria, VA
- 8 3. Department of Computer Science, Purdue University, West Lafayette, IN
- 9 4. Department of Computer Science, Massachusetts Institute of Technology, Cambridge,
10 MA
- 11 5. Department of Computer Science, University of Washington, Seattle, WA
- 12 6. Emerging Diagnostic and Investigative Technologies, Department of Pathology and
13 Laboratory Medicine, Dartmouth Health, Lebanon, NH
- 14 7. Dartmouth Cancer Center, Lebanon, NH
- 15 8. Department of Epidemiology, Dartmouth College Geisel School of Medicine, Hanover,
16 NH
- 17 9. Department of Molecular and Systems Biology, Dartmouth College Geisel School of
18 Medicine, Hanover, NH
- 19 10. Integrative Neuroscience at Dartmouth (IND) graduate program, Dartmouth College
20 Geisel School of Medicine, Hanover, NH
- 21 11. Department of Community and Family Medicine, Dartmouth College Geisel School of
22 Medicine, Hanover, NH
- 23 12. Department of Dermatology, Dartmouth Health, Lebanon, NH
- 24 13. Program in Quantitative Biomedical Sciences, Dartmouth College Geisel School of
25 Medicine, Hanover, NH

26
27 * To whom correspondence should be addressed: joshua.j.levy@dartmouth.edu
28

29 **Corresponding Author Contact Information:**

30 Joshua J. Levy PhD

31 Assistant Professor of Pathology and Dermatology

32 Adjunct Assistant Professor of Epidemiology

33 Faculty, Quantitative Biomedical Sciences

34 Machine Learning Co-Director, Emerging Diagnostic and Investigative Technologies

35 Biostatistics and Bioinformatics Shared Resource, Dartmouth Cancer Center

36 Dartmouth-Hitchcock Medical Center

37 1 Medical Center Drive, Department of Pathology and Laboratory Medicine, Lebanon, NH

38 03756

39 Phone: (925) 457-5752 | Email: joshua.j.levy@dartmouth.edu
40

41 **Abstract**

42 Over 150,000 Americans are diagnosed with colorectal cancer (CRC) every year, and annually
43 over 50,000 individuals will die from CRC, necessitating improvements in screening,
44 prognostication, disease management, and therapeutic options. Tumor metastasis is the
45 primary factor related to the risk of recurrence and mortality. Yet, screening for nodal and distant
46 metastasis is costly, and invasive and incomplete resection may hamper adequate assessment.
47 Signatures of the tumor-immune microenvironment (TIME) at the primary site can provide
48 valuable insights into the aggressiveness of the tumor and the effectiveness of various
49 treatment options. Spatially-resolved transcriptomics technologies offer an unprecedented
50 characterization of TIME through high multiplexing, yet their scope is constrained by cost.
51 Meanwhile, it has long been suspected that histological, cytological and macroarchitectural
52 tissue characteristics correlate well with molecular information (e.g., gene expression). Thus, a
53 method for predicting transcriptomics data through inference of RNA patterns from whole slide
54 images (WSI) is a key step in studying metastasis at scale. In this work, we collected and
55 preprocessed Visium spatial transcriptomics data (17,943 genes at up to 5,000 spots per patient
56 sampled in a honeycomb pattern) from tissue across four stage-III matched colorectal cancer
57 patients. We compare and prototype several convolutional, Transformer, and graph
58 convolutional neural networks to predict spatial RNA patterns under the hypothesis that the
59 transformer and graph-based approaches better capture relevant spatial tissue architecture. We
60 further analyzed the model's ability to recapitulate spatial autocorrelation statistics using SPARK
61 and SpatialDE. Overall, results indicate that the transformer and graph-based approaches were
62 unable to outperform the convolutional neural network architecture, though they exhibited
63 optimal performance for relevant disease-associated genes. Initial findings suggest that different
64 neural networks that operate on different scales are relevant for capturing distinct disease
65 pathways (e.g., epithelial to mesenchymal transition). We add further evidence that deep
66 learning models can accurately predict gene expression in whole slide images and comment on
67 understudied factors which may increase its external applicability (e.g., tissue context). Our
68 preliminary work will motivate further investigation of inference for molecular patterns from
69 whole slide images as metastasis predictors and in other applications.

70
71 **Keywords:** Spatial transcriptomics, deep learning, graph neural network, transformers,
72 colorectal cancer, histomorphology

73 1. Introduction

74 Colorectal cancer is the third leading cause of cancer-related death in the United States, and
75 there are disparities in screening and outcomes between age, race, and gender ¹. CRC
76 incidence is rising among younger adults who are not typically incorporated into screening
77 programs, illustrating the importance of developing timely and lower-cost prognostication
78 methods to better assess the tumor's malignant potential. Currently, the Pathological TNM-
79 staging system (pTNM), which determines staging based on the impact of local invasiveness–
80 histological stage (T-stage), and metastatic potential– nodal (N-stage) and distant (M-stage)
81 metastasis, is the most predictive factor for risk of recurrence and prognosis. Metastasis, in
82 many cases, is challenging to assess at the time of primary tumor resection ². For instance,
83 specimen inadequacy often hinders the complete inference of nodal involvement ³. It is thus
84 crucial to develop orthogonal, less invasive, but equally informative technologies that can shed
85 light on disease pathology and prognosis. One promising direction is to study the Tumor
86 Immune Microenvironment (TIME)– the amalgamation of immune cells, chemokines, cytokines,
87 and other immune modulators, etc. that accrete at the invasive front and inside the tumor at the
88 primary site ⁴⁻⁶. Recent studies have demonstrated that monocyte/lymphocyte immune infiltrates
89 and their spatial distribution, density, and relationships play an important role in providing a
90 coordinated anti-tumoral response. Yet, the full importance of TIME has not been elucidated, as
91 most clinical studies consider either a few canonical markers at a time (e.g., immunoscore,
92 which assesses cytotoxicity at the primary site) or only study cell mixtures which lack a single-
93 cell or spatial dimension ⁷.

94
95 Spatially-resolved transcriptomics (spatial omics), as enabled through technologies such as 10x
96 Genomics Spatial Transcriptomics (ST, Pleasanton, CA) or Nanostring GeoMX Digital Spatial
97 Profiling (DSP, Seattle, WA), is an actively growing area of research that provides rich
98 information about how different areas of tissue interact by analyzing highly multiplexed gene
99 expression at staggering spatial resolution. These technologies can be configured to study the
100 distribution, density, and spread of tumor-infiltrating lymphocytes (TILs) as they may relate to
101 concomitant somatic alterations ^{8,9}. Assay costs are currently exceedingly high, as profiling just
102 four capture areas can cost tens of thousands of dollars, though costs are being driven
103 downwards with new advances in chemistry and lower sequencing costs. Thus, sufficiently
104 powering spatial transcriptomic association studies or extending their generalizability of the
105 inferences to specific patient subgroups that lie outside of these small cohorts is challenging
106 due to cost. In comparison, tissue slides stained with hematoxylin and eosin (H&E) to assess
107 tissue histomorphology are routinely ordered at a very low cost, and there is ample evidence to
108 suggest that many concurrent molecular alterations coincide with morphological features. Thus,
109 the prediction of RNA expression using image data across a slide presents an opportunity to
110 reveal critical prognostic information for patients at a lower cost, which can motivate relevant
111 downstream analyses.


112
113 Deep learning approaches, which rely on using multi-layer artificial neural networks (ANN), have
114 proven instrumental for image analyses in the context of digital pathology ¹⁰. Of relevance for
115 this study is the assessment of whole slide images (WSI), digitized tissue slides, from which
116 machine learning applications can predict the primary site of a metastatic lesion, tumor stage,
117 and the outcome of immunohistochemical stains. Convolutional neural networks (CNNs), a type
118 of predictive machine learning model, are powerful tools for extracting dense information from
119 high-dimensional image data. Prior works have employed these algorithms to extract
120 morphological features from H&E-stained tissue to complement whole transcriptome analyses.
121 As WSI can extend to hundreds of thousands of pixels along each spatial dimension, they are
122 usually broken into subimages to enable efficient computation. Of relevance to our research

123 topic, He et al. (2020) used a DenseNet-101 model to regress on co-localized gene expression
124 levels¹¹, and Levy-Jurgensen et al. (2020) employed an InceptionV3 model to detect
125 dichotomized gene expression for given patches of tissue¹². However, these techniques do not
126 analyze the potential for integrating spatial context outside the patch-level (i.e., spatially
127 correlated patches are assumed to be independent and identically distributed), and, therefore
128 may miss larger macroarchitectural contextual cues of aberrant expression.
129

130 Zeng et al. (2022) and Pang et al. (2021) investigated approaches to integrate broader spatial
131 context into their gene expression prediction models by using vision transformers and
132 demonstrated that it is possible to outperform convolutional architectures that make predictions
133 on individual patches (e.g., ST-Net)^{13,14}. However, there remain several unknowns, such as 1)
134 the scale of tissue features relevant for inferring RNA, 2) how well these models preserve global
135 spatial expression characteristics (e.g., patterns of clustering), 3) whether relevant domain
136 knowledge can make inferences more informative, and 4) whether these effects depend on the
137 specific genes under study (i.e., what resolution/architectural context is optimal for specific
138 genes and what does it say about the tumor biology). Furthermore, many spatial omics studies
139 attempt to study one slide, where potential endogeneity is introduced by a matter of spatial
140 distance between collection sites.
141

142 Here, we compared a convolutional neural network and a graph attention network for inferring
143 spatially co-registered gene expression from WSI. We comment on the role the tissue
144 macroarchitecture may play in RNA inference as elucidated by changing subimage size and the
145 use of contextual models. We also assessed performance on a subset of immune-related genes
146 and how spatial characterization varies across these models/factors and slides. These
147 explorations will motivate future downstream work to characterize factors pertaining to tumor
148 nodal/distant metastasis.
149

150 2. Material and Methods



151
152
153 **Figure 1. Overview of tested model architectures:** Whole Slide Images are divided into
154 patches co-localized with the Visium spots and an Inception model is used to predict counts and
155 dichotomized expression for 1000 genes; Features derived from Inception model are
156 additionally fine-tuned using graph neural network for inference; inferred expression profiles are
157 compared to the ground truth through a cluster analysis, spatial autocorrelation tests and
158 pathway analysis

159 2.1. Overview

160 The primary goal of this work is to predict the gene expression detected by a Visium spot at any
161 given location on the slide. Our method is as follows (**Figure 1**):

- 162 1. **Data Collection:** Acquire H&E whole slide images (WSI), and spatially-registered
163 Visium assayed spatial transcriptomics slides from 4 stage-pT3 matched colorectal
164 cancer patients at Dartmouth Hitchcock Medical Center, two patients without metastasis,
165 one with nodal metastasis only and one with both nodal and distant metastasis.
- 166 2. **Preprocess:** Preprocess gene expression and WSI subarrays.
- 167 3. **Model Development:** Configure two modeling approaches: convolutional neural network
168 and graph attention neural networks, the latter leveraging larger spatial context. These
169 models will predict both binary (dichotomized expression) and count-based (continuous;
170 zero-inflated negative binomial) objectives. We also configured additional approaches
171 (e.g., Transformer) for comparison.
- 172 4. **Capture surrounding tissue context at different scales:** Ablation study over patch
173 size to determine whether relevant biological information is encoded outside the Visium
174 collection spot area.
- 175 5. **Leave one-patient-out cross-validation:** Evaluation on held-out slides/patients as a
176 measure of external applicability.
- 177 6. **Recover Spatial Biology Inferences:** Spatial autocorrelation tests for the capacity of
178 models to draw similar spatial inferences.

179 2.2. Data Collection

180
181 The primary dataset utilized in this study was acquired from four pathologic T Stage-III (pT3)
182 matched (pTNM system) colorectal cancer patients at Dartmouth Hitchcock Medical Center,
183 determined through a retrospective review of pathology reports from 2016 to 2019 following IRB
184 review and approval. These four patients were drawn from a set of 36 patients included in a
185 prior study¹⁵— half of the patients had concurrent tumor metastasis (slides A1 and B1 had tumor
186 metastasis; slides C1 and D1 did not have tumor metastasis) and were otherwise matched on
187 age, sex, tumor grade, tissue size, mismatch repair (MMR) status, and tumor site using iterative
188 patient resampling with t-tests for continuous variables and fisher’s exact tests for categorical
189 variables. The four patients were subselected to restrict the tumor site (three in the right colon,
190 one in the transverse colon), grade (three grade 1, one grade 2), node status (two metastasis
191 cases with N-1a), and account for differences in sex (50% female within both the non-
192 metastasis and metastasis groups). We restricted the cohort to patients without MMR
193 deficiencies as determined through immunohistochemistry (IHC) to control for microsatellite
194 instability status. Tissue blocks were sectioned into 10-micron thick layers, and specific capture
195 areas that contained various distinct macroarchitectural regions (all containing epithelium,
196 tumor-invasive front, intratumoral, lymphatics, etc.) were annotated by the practicing pathologist.
197 A histotechnician carefully extracted / manually cut these capture areas from the tissue, and
198 slides were sent to the Single Cell Genomics Core in the Center for Quantitative Biology for
199 simultaneous H&E staining, imaging, and Visium profiling. After a deparaffinization step, spatial
200 transcriptomics uses spatially-tagged oligo barcodes to 1) register spatial coordinates to
201 collection spots, bound to the mRNA with a poly(A) tail for 2) reverse transcription into cDNA,
202 after 3) permeabilization, and 4) sequencing for mRNA profiling. This allows for
203 unbiased/gridded profiling of up to 5,000 spots (1-10 cells/spot) per 6.5mm by 6.5mm capture
204 area.
205

206 **2.3. Preprocessing**

207 Spatial gene expression profiles contain information for 17,943 genes at almost 5,000 locations
208 per slide (after filtering out non-tissue– total number of Visium dots: 4950, 4922, 4887, and 4169
209 per slide), sampled in a honeycomb formation. Each Visium spot covers a circular capture area
210 with a diameter of 130 pixels at 20x magnification. After sequencing, we used the *SpaceRanger*
211 package to preprocess the Visium reads into gene count matrices.
212

213 As whole slide images (WSIs) derived from the Visium capture areas (size of capture area– 6.5
214 x 6.5 mm) span thousands of pixels along each dimension, we subdivided the image into square
215 patches centered on the Visium spot. We associated the gene expression of each patch based
216 on the Visium spot at the center of the patch and ignored expression at other spots contained
217 within the patch.

218 **2.4. Inference Targets**

219 We used the SpatialDE library to select the top 1000 genes based on their mean fraction of
220 spatial variance (FSV) across all slides (i.e., selected genes which exhibited the greatest spatial
221 variation across the four slides). We tested the capacity of our models to recover expression for
222 all 1000 genes based on dichotomized expression (binary classification) and the original counts
223 (regression) ¹⁶.
224

225 For binary classification, we classify tiles as having a “high” expression for a gene if its individual
226 expression is greater than the median for that slide, as shown by Levy-Jurgensen et al.. For
227 binary tasks, we used a weighted binary cross-entropy loss. The loss was independently taken
228 for positive and negative Visium spots and summed together to account for unbalanced labels.
229

230 We model the gene expression distribution for regression tasks as a negative binomial
231 distribution with zero inflation. The model predicts the parameters of the distribution (mean μ ,
232 dispersion factor σ , and inflation of zero count π) and is optimized with negative log-likelihood
233 loss. The inferred value is equal to the expected value of the negative binomial distribution
234 (accounting for zero inflation): $(1 - \pi)\mu + \pi(0) = (1 - \pi)\mu$.

235 **2.5. Modeling Approaches**

236 First, we compare the performance of the following models using the dichotomized labels and
237 continuous regression objectives. For these models, we sought to establish whether increasing
238 the spatial receptive field by varying the patch size (ablation study) and training graph attention
239 networks (GATs) positively impacted our capacity to predict spatial gene expression. All models
240 featured an output layer, which simultaneously predicted the expression of all selected genes
241 (**Figure 1**). Details of these approaches can be found below:
242

243 **2.5.1. Local Patch Prediction Model:** We initialized our model using InceptionV3 weights
244 (Szegedy et al., 2015) ¹⁷. InceptionV3 was chosen because it has demonstrated high
245 performance in gene imputation studies by Levy-Jurgensen et al. These models are trained for
246 25 epochs with a learning rate of 0.0001 and a batch size of 32. The patch size labeled
247 Inception models they were configured to make predictions on (i.e., amount of incorporated
248 surrounding information): **Inception-256** (256 pixels), **Inception-512** (512 pixels), and
249 **Inception-768** (768 pixels) (model suffix indicates patch size).
250

251 **2.5.2. Contextualized Patch Prediction Models:** The Visium spots lie on a hexagonal array, each
252 of which can be treated as a node in a graph, each connected to other Visium spots within 150

253 pixels. After training the InceptionV3 models from our local patch classification experiments, we
254 extracted patch image embeddings (e.g., n-dimensional descriptive vector) for each Visium spot
255 from the penultimate layer of the trained Inception-256 model. We test a graph attention network
256 (GAT) to see how iterative message-passing can improve model performance. We also
257 compared these results to that obtained using a Vision Transformer (ViT)^{18(p16)}. GAT models
258 were labeled by the number of graph attention layers used to make predictions (i.e., the amount
259 of incorporated surrounding information; the number of layers dictates the size of the
260 neighborhood; eight attention heads per layer): **GAT-1** (1 layer), **GAT-2** (2 layers), and **GAT-4**
261 (4 layers) (model suffix indicates the number of layers). ViT models were labeled by the size of
262 the patch used to form contextual embeddings: **ViT-224** (224-pixel patch sizes) and **ViT-384**
263 (384-pixel patch sizes).

264 *2.5.3. Data Augmentation during training and hyperparameters:* To improve the robustness of
265 the model results to new tissue contexts, we transformed patch images by shifting and scaling
266 the pixel intensities by the mean and variance of ImageNet. Then, we applied color jitter and
267 random rotations; between -15 and 15 degrees. Random horizontal and vertical flips also
268 augment patches if they are not used in the GAT. Through a coarse hyperparameter search,
269 learning rates were set to 1e-4, and models were trained for 25 epochs. Batch sizes for the
270 Inception model were set to 32, save for the regression models for patch sizes 512 and 768,
271 where batch sizes were set to 16 and 8, respectively.

272

273 **2.6. Comparison of Model Performance**

274

275 To compare model and patch-size performances, we performed leave-one-slide-out cross-
276 validation (CV), where three of the four slides were used for training/validation, and the final
277 slide was used for testing. This scheme was repeated four times to report on test performance
278 across all four slides in an unbiased manner using macro-averaged (across slides) median
279 (across genes) area under the receiver operating curve (AUROC) and Average Precision (AP)
280 statistics for the binary outcome and correlation coefficients (e.g., Spearman) to compare true
281 versus predicted counts. Non-parametric bootstrapping was used to assess statistical
282 significance through the calculation of a 95% confidence interval. During cross-validation, we
283 use the same set of *InceptionV3* embeddings to train the contextual models (i.e., GAT) that
284 corresponded to the same cross-validation fold. We acknowledge that these statistics could also
285 vary by models, patch size, and slides, so we plotted scatters of test AUCs of each gene to
286 compare these factors in a pairwise manner (e.g., for slide 1, comparing Inception to GAT, or
287 patch size 256 to 768) to draw additional inferences on suitable modeling approaches for a
288 subset of genes. Identifying a subset of genes that obtained optimal performance for one
289 approach versus another was as important as comparing overall performance. These
290 performance differences could suggest relevant tissue features at different scales. For instance,
291 the GAT could extract features from the larger macroarchitecture, indicating its relevance for a
292 gene that does not predict well from *InceptionV3*.

293

294 **2.7. Model Interpretation through Pathway Analysis and Gene Embeddings**

295

296 Due to fundamental limitations in tissue biology, it is unrealistic to expect that every gene can be
297 predicted from tissue histology. We sought to establish which types of genes could be inferred
298 from histology through pathway analysis. Using the *Elsevier Pathways* database available
299 through the Enrichr package, we performed a pathway analysis of the top 250 genes ranked by
300 AUROC averaged across the CV folds¹⁹. Enrichr reports overrepresented pathways using a
301 modified fisher's exact test. Detected pathways were filtered based on tissue specificity (i.e.,

302 could reasonably be involved with the colon). To determine whether different pathways could be
303 inferred from different tissue contexts, pathway analysis results were compared across models.

304 We also sought to assess how well the predicted gene expression profiles recapitulated
305 relationships/clustering between the Visium spots. This was accomplished through the
306 comparison of Uniform Manifold Approximation and Projection (UMAP) embeddings for the
307 ground truth and predicted expression profiles (on held-out slides) using *InceptionV3* and GAT
308 ²⁰. Ground truth and predicted gene expression profiles were projected to a lower dimensional
309 space using AlignedUMAP to preserve the orientation/alignment between the ground truth and
310 predicted expression profiles (i.e., positioning of Visium spots across projections is relatively
311 preserved) to enable comparison between the approaches. Visium spots corresponding to the
312 ground truth UMAP projections were clustered using Hierarchical density-based clustering
313 (HDBSCAN) ²¹. HDBSCAN also identified outlier Visium spots removed from the cluster
314 analysis and scatterplots for all three datasets (ground truth, *InceptionV3*, GAT). Mapper, a
315 Topological Data Analysis method, was used to provide topological summaries of the
316 embeddings by reducing the number of points based on overlap and connectivity ²²⁻²⁴. Mapper
317 embedding plots for *InceptionV3* and GAT were colored using the cluster information from the
318 ground truth expression to qualitatively assess topological consistency (i.e., were relationships
319 between Visium spots preserved). This procedure was repeated across the held-out test slides.


320 **2.8. Recapitulating Spatial Biology through Spatial Autocorrelation Tests**

321 In addition to tissue clustering, spatial variation is often used as a proxy for explaining the
322 diversity of cellular lineages interacting across the tissue slide. While this factor alone is not an
323 exhaustive assessment of spatial biology, this served as a target for our preliminary assessment
324 (an exhaustive exploration of spatial analyses is out-of-scope of this work, although it is a future
325 direction). After performing cross-validation, we sought to investigate the ability of our
326 algorithms to recapitulate known spatially variable genes on each of the held-out slides from the
327 cross-validation folds. We used two libraries to determine spatially variable (SV) genes:
328 SpatialDE and SPARK-X ²⁵. Gene expression counts were summed to create a total count
329 matrix. Genes with low overall expression across the slide (i.e., below a threshold of 30% slide
330 coverage) were removed. The data was then transformed to a normal distribution (by Anscombe
331 transform) to account for the negative binomial distribution of the gene expression. Since
332 SpatialDE's computation time increases cubically with each additional expression patch, we
333 reduced the resolution of the Visium data through 2x2 median pooling (i.e., taking median
334 expression for specific genes from 2x2 neighborhoods). The reduced memory requirements
335 allowed us to perform further histo-molecular assessments on the images, including clustering
336 based on spatial variability.

337
338 Using SpatialDE, we extracted the Fraction of Spatial Variance (FSV) and p-values for each
339 gene from the ground truth set. In addition, we used SpatialDE's Automatic Expression
340 Histology (AEH) to identify 5 groups of genes that were co-expressed spatially from the ground
341 truth data. Separately, we ran SPARK/SPARK-X on the 1000 genes from each held-out
342 validation slide, reporting projection and adjusted P-value (Bonferroni-corrected) statistics. We
343 separately ran this procedure for the ground truth expression and predicted expression profiles.
344 As an indication of performance, we expected p-values derived for the projection covariance
345 function for both the inferred and original expression data to correlate well with each other for
346 each slide. This was accomplished using the Fisher's exact test after dichotomizing spatial
347 autocorrelation statistics into "high autocorrelation" (low p-value) and "low autocorrelation" (high
348 p-value) and similar dichotomization for statistics extracted from the inferred expression.

349 Thresholds for dichotomization were chosen to maximize the magnitudes of the Fisher's exact
350 test statistics. Dichotomized spatial autocorrelation was cross-tabulated across the genes to
351 report odds ratios with p-values. An odds ratio and corresponding confidence interval of more
352 than one (i.e., statistically significant) would suggest the ability of the model to recapitulate
353 spatial autocorrelation from the slide. Separately, we sought to assess whether genes that were
354 predicted with high accuracy (AUC) were spatially autocorrelated using a similar methodology
355 (i.e., comparing dichotomized spatial autocorrelation on the ground truth expression with
356 dichotomized AUC for each modeling approach). We also compared model accuracies between
357 AEH groups of co-expressed genes identified from SpatialDE using Kruskal-Wallis ANOVA
358 statistical tests. Similar to the AUC comparison, we performed comparisons across models,
359 patch sizes, and slides. It should be noted that these analyses were done on the top 1000
360 spatially variable genes; dichotomized autocorrelation is for this reference group. For the
361 original and inferred expression, genes which exhibited spatial autocorrelation which differed
362 between patients with and without metastasis were selected for a pathway analysis using the
363 *MSigDB Hallmarks* gene sets via the Enrichr software.

364 **3. Results**



365
366
367
368

Figure 2: Model Performance Comparison: A) Boxenplots which depict the distribution of AUC values for predicting dichotomized expression across all 1000 filtered genes; **B)** Scatter plot of genes representing individual cross-validated AUC values for GAT-4 versus Inception-

369 768; while overall Inception outperforms GAT, there are several genes from which GAT
370 outperformed Inception

371 **3.1. Model Comparison**

372 First, we assessed the ability of the Inception model to predict gene expression without
373 considering the surrounding tissue macroarchitecture. Across the whole transcriptome, we
374 noted moderately strong concordance between the predicted and actual expression across the
375 held-out slide folds.

376
377 *3.1.1. Impact of patch size to leverage surrounding spatial context:* Importantly, the model
378 achieved optimal performance by increasing access to the surrounding macroarchitecture by
379 increasing the patch size.

380
381 *3.1.2. Impact of model architecture to leverage surrounding spatial context:* After optimizing
382 model architectures, the Inceptionv3 model appeared to outperform the GAT and Transformer
383 approaches for the whole transcriptome assessment. This was true for both classification and
384 regression modeling objectives. The GAT-1 model outperformed the GAT-4 model, which
385 incorporated more of the surrounding tissue context, for the classification task, though GAT-4
386 outperformed GAT-1 for regression and demonstrated a similar capacity to predict count
387 outcomes as Inception-512 (**Figure 2; Table 1**). A breakdown of these model performances for
388 individual held-out validation slides can be found in the appendix (**Supplementary Table 1;**
389 **Supplementary Figures 1-2**).

390
391 *3.1.3. GAT outperforms Inception on a subset of genes:* While overall, Inception outperformed
392 GAT, it is important to recognize that there are many genes for which GAT achieves superior
393 performance (**Figure 2B; Table 2; Supplementary Figure 1**). This was different than
394 comparing multiple Inception models with different patch sizes, where clearly Inception-768
395 outperformed Inception-256 on nearly all relevant genes (a scatter plot of the specific gene-level
396 AUC for specific genes for patch size 256 compared to 768 can be found in **Supplementary**
397 **Figure 2**). As different models demonstrate exemplary performance on different subsets of
398 genes, the combined accuracy (AUC) across the genes (i.e., selecting top performing model for
399 each gene based on CV-AUC) is 0.798 (95% CI [0.795-0.802]); the combined AP score is 0.67
400 (95% CI [0.659-0.677]) (**Figure 2**) (**Top Overall Model**).

401
402
403 **Table 1. Comparison of model performance for predicting dichotomized and log-**
404 **transformed expression for genes across the whole transcriptome.** These statistics are
405 created by taking the median of each performance statistic across all genes, averaged across
406 held-out slides.

Model	Classification		Regression	
	AUROC	AP	Spearman	Pearson R
Inception-256	0.769±0.004	0.587±0.011	0.439±0.011	0.466±0.014
Inception-512	0.782±0.005	0.61±0.013	0.456±0.011	0.496±0.013
Inception-768	0.79±0.006	0.621±0.012	0.479±0.011	0.538±0.013
GAT-1	0.746±0.003	0.528±0.014	0.302±0.009	0.309±0.009
GAT-2	0.676±0.002	0.444±0.01	0.409±0.01	0.446±0.01
GAT-4	0.703±0.004	0.459±0.012	0.406±0.01	0.428±0.011


ViT-224	0.757±0.005	0.573±0.012	0.432±0.011	0.458±0.013
ViT-384	0.762±0.004	0.57±0.012	0.442±0.012	0.473±0.014

407
408
409

Table 2: Top 10 performing genes for Inception-768, Inception-256 and GAT-4, ranked by AUC

Name	Top-10 Inception			Name	Top-10 GAT		
	Inception-768	Inception-256	GAT		Inception-768	Inception-256	GAT
<i>KRT8</i>	0.889	0.850	0.491	<i>TRIP12</i>	0.753	0.745	0.829
<i>SI00AA10</i>	0.884	0.846	0.714	<i>PGM3</i>	0.749	0.740	0.829
<i>CDH1</i>	0.880	0.848	0.510	<i>TMEM238</i>	0.855	0.825	0.825
<i>RNF43</i>	0.879	0.847	0.556	<i>SYNM</i>	0.700	0.674	0.823
<i>KRT18</i>	0.877	0.838	0.723	<i>SMAP1</i>	0.771	0.757	0.822
<i>SI00A6</i>	0.875	0.842	0.606	<i>SERPINE1</i>	0.594	0.581	0.821
<i>RAB25</i>	0.873	0.844	0.545	<i>LSM4</i>	0.844	0.818	0.820
<i>AXIN2</i>	0.873	0.844	0.610	<i>GRIPAP1</i>	0.766	0.752	0.818
<i>EPCAM</i>	0.873	0.834	0.491	<i>TSPO</i>	0.822	0.796	0.818
<i>TNS4</i>	0.871	0.841	0.801	<i>HLA-DRA</i>	0.612	0.618	0.816

410



411
412
413
414
415
416
417
418
419


Figure 3. Comparison of log-scaled heatmaps of the ground truth gene expression (top) and output probabilities for above-median expression from the dichotomized classifiers: A-C) Inception-768 classifier's predictions, generating heatmaps for A) RAB25, B) TNS4, and C) AXIN2 genes; all predictions from the held-out test set. The corresponding median AUROCs for these genes were 0.873, 0.871, and 0.873. D) AXIN2 imputation on slide B1 with GAT. E) AXIN2 imputation on slide D1 with GAT.

420 3.2. Pathway Analysis

421
422 The top-performing genes by AUROC for both types of models were also highly related to tumor
423 aggression and migration. For instance, *CDH1*, heavily implicated with tumor suppression,
424 achieved AUROC of 0.880²⁶. *RAB25* (**Figure 3A**), which can serve as a tumor suppressor or
425 oncogene depending on the context, obtained an AUROC of 0.879. *TNS4* has been heavily
426 implicated for multiple prognostic outcomes following surgery and was predicted with an AUC of
427 0.871²⁷. *AXIN2* (**Figure 3C-E**), which inhibits the Wnt signaling pathway and serves to regulate
428 immune cell infiltration²⁸, was detected with an AUROC of 0.873. The pathway analysis
429 corroborated these findings and was highly relevant for metastasis formation. For instance,
430 genes associated with cancer metastasis, cell motility and proliferation, glycolysis, and the
431 epithelium to mesenchymal transition were identified by both models. Interestingly, the GAT
432 model was able to identify genes related to anti-EGFR therapy resistance in colorectal cancer
433 (**Supplementary Table 2**).
434

435 Inferred Spatial Expression is Topologically Consistent with Ground Truth

436



437
438 **Figure 4: UMAP Embeddings of True and Predicted Gene Expression** for slides **A) A1, B)**
439 **B1 and C) D1**; embedding plots are summarized using Mapper, which flexibly clusters the
440 expression data with overlapping clusters containing multiple Visium spots; Mapper nodes are
441 sized by the number of associated spots and colored by the dominant cluster in the set of node-
442 associated spots with cluster assignments determined using HDBSCAN; outliers were filtered
443 from these embedding plots and the cluster assignments plotted over the WSI on the right
444

445 Visual inspection of mapper diagrams of clustered UMAP embeddings illustrates topological
446 consistency (i.e., preserve relationships) between the predicted expression and the ground truth
447 (**Figure 4**). Qualitatively, the gene expression embeddings produced from Inception appear to
448 be more closely aligned with the ground truth embeddings across the tissue types (e.g.,


449 **Figure 4 A, C**, where clusters are placed in the approximately same area for Ground Truth and
450 Inception in the Mapper diagrams).
451

452 **3.3. Spatial Autocorrelation**

453 We also compared the capabilities of each modeling approach for their ability to recapitulate
454 slide-level spatial autocorrelation parameters. Results indicate a large significant positive
455 association between predicted and actual spatial autocorrelation for both Inception and GAT
456 approaches. For half of the held-out slides, GAT demonstrated a larger effect estimate than
457 Inception (**Table 3**).

458
459 Separately, results indicate that highly spatially autocorrelated genes, as determined using the
460 actual gene expression, were predicted with higher accuracy using Inception and GAT versus
461 genes, which lacked spatial variation (**Table 3**). These models varied in their ability to associate
462 spatial variation with model accuracy. For Inception, there was a large statistically significant
463 effect (**Figure 5**), while spatial variation was not as associated with accuracy for the GAT– i.e.,
464 there was a statistically significant association for the first two slides and no statistically
465 significant effect for the final two. For the Inception model, groups of genes that tended to be co-
466 expressed, as determined through the AEH analysis on the raw expression data, were found to
467 have widely different accuracies (**Table 3; Supplementary Figures 3-5**). Similar to the spatial
468 variation analysis, GAT model accuracy did not vary substantially between AEH groups
469 determined from the raw expression data.

470
471 Using the ground truth, Inception, and GAT results, we identified the set of genes, which
472 exhibited different spatial variation for primary sites with (A1, B1) and without metastasis (C1,
473 D1) based on the dichotomized thresholds. Through a pathway analysis (gene set testing of
474 Cancer Hallmark genes), genes that were differently autocorrelated were related to the epithelial
475 to mesenchymal transition (**Supplementary Table 3**).
476



477
478 **Figure 5. Boxenplots illustrating the predictive accuracy of Inceptionv3 (AUC, y-axis)**
479 **across genes, separated by whether highly significant spatial variation was reported**
480 **(blue versus orange, x-axis); gathered from validation slides held-out of the training/validation**
481 **set. The positive association demonstrates higher accuracy for genes with significant spatial**
482 **variability (i.e., not distributed randomly); these genes were more accurately predicted by our**
483 **RNA inference model. A-D) correspond to slides A1-D1, respectively**
484
485

486 **Table 3: Statistical testing results from spatial autocorrelation analysis, comparing: A)**
487 **Spatial autocorrelation from raw expression (high/low) with inferred spatial autocorrelation from**
488 **predicted expression values (high/low); B) Spatial autocorrelation from raw expression**
489 **(low/high) with model AUC (high/low); C) Whether model accuracy changed depending on the**
490 **AEH group; A) and B) were determined through Fisher's exact tests while C) utilized Kruskal-**
491 **Wallis ANOVA testing**

Slide	Model	Recover Spatial Autocorrelation		Spatial Autocorrelation vs AUC		AEH group vs AUC
		OR	P-Value	OR	P-Value	P-Value
A1	Inception	722.27	6.55e-65	0.01	4.05e-99	1.78e-39
B1		40.09	1.30e-34	0.01	8.29e-85	3.93e-162
C1		68.82	1.25e-16	0.07	1.05e-57	2.00e-119
D1		92.18	1.30e-20	0.02	5.41e-96	2.46e-166
A1	GAT	101.64	1.46e-61	0.45	2.02e-05	9.52e-02

B1	51.12	1.16e-24	0.58	0.01	1.37e-01
C1	24.80	3.10e-06	0.93	0.66	8.54e-01
D1	99.15	5.06e-22	0.99	1.00	6.68e-01

492

493 **4. Discussion**

494

495 Assessment of Colon cancer tumor recurrence risk depends on the ability to assess lymph node
496 status. For cases where lymph nodes are unable to be completely assessed, leveraging
497 information found in the tumor immune microenvironment at the primary resection site
498 presents a viable alternative. Yet most technologies to assess the primary site lack a spatial
499 component (e.g., bulk expression), which does not enable a comprehensive characterization of
500 the tissue. Spatial transcriptomic technologies enable high multiplexing at incredible spatial
501 resolution. Due to both fiscal and sampling (i.e., placement of capture area) constraints,
502 findings are not likely to be clinically actionable or reproducible through a low-cost test.
503 Inferring a spatial digital biomarker from a routine histological slide (WSI) has the potential to
504 enable high-throughput tissue characterization for the creation of nascent decision-making aids
505 which can complement existing specimen findings. In this study, we explored the potential for
506 deep learning models to predict spatial gene expression from formalin-fixed specimens, the
507 ability to recapitulate well known spatial findings, and comment on the degree to which spatial
508 information at higher-order contexts (i.e., macroarchitecture) plays a role in modeling spatial
509 expression.

510

511 We add further evidence that deep learning models can accurately predict gene expression in
512 whole slide images. Furthermore, we demonstrate that increasing the receptive field can
513 improve the performance of certain subsets of genes. Interestingly, although InceptionV3
514 outperformed other modeling approaches overall, this did not apply to all genes. We noted that
515 certain genes were predicted more effectively at local spatial resolutions (Inception) while
516 others benefited from considering a broader architectural context (GAT). For instance, we
517 noticed that *COL6A1* and *COL6A2* were consistently predicted better by the GAT model as
518 compared to Inceptionv3²⁹⁻³¹. *COL6A1* is a crucial component of collagen secretion,
519 extracellular matrix maintenance, and mesenchymal phenotype promotion. While both models
520 demonstrated the capacity to recapitulate well-known cancer markers, it was clear that certain
521 genes can be better predicted by considering receptive field size and choosing a model that
522 best incorporates this spatial information.

523

524 Spatial autocorrelation was recapitulated for these slides from the deep learning model
525 predictions. We noticed that increases in modeling accuracy were associated with spatial gene
526 expression variation. Genes that were differentially autocorrelated between metastatic and non-
527 metastatic tumors corroborated with well-established oncogenic pathways. This supports our
528 overarching modeling approach to characterize spatial heterogeneity. As some genes were
529 better predicted using the broader spatial architecture, it would make sense to decide which
530 modeling approach to utilize on a gene-by-gene basis and whether the local versus spatial
531 context is preferred. This allows for the selection of optimal modeling approaches in a gene-
532 specific manner to extend the broad applicability of our framework across all disease-relevant
533 genes.

534

535 Importantly, the techniques featured in this work will prove useful for inferring gene expression
536 on slides from external cohorts. This is necessary due to the prohibitive costs of spatial
537 transcriptomics. If validated properly on a slightly larger set of slides while carefully controlling
538 for potential confounders (e.g., site, MMR status, etc.), these methods may overcome sources
539 of patient-specific batch effects to allow the report of less biased effect estimates for large-
540 scale cohort studies. Validation efforts on these held-out slides can feature validation
541 assessments such as Spark-X and SpatialDE to ensure spatial heterogeneity from the inferred
542 expression data is similar to the initial internal validation cohort. To this end, we achieved
543 remarkable performance for the ability to predict spatial heterogeneity, which will potentially
544 help power future studies elucidating spatial transcriptomic predictors of colon metastasis.

545
546 Our results did not support the hypotheses that, overall, spatial gene expression estimation
547 would benefit from message-passing between patch locations via transformer models and
548 graph convolutional networks. However, these neural networks outperform local patch
549 prediction across a large set of genes, suggesting the relevance of these methods for genes
550 which leverage the spatial context. For GAT, underperforming genes can potentially be
551 explained by the fact that graph convolutional networks tend to smoothen features (Li et al.,
552 2018), which may weaken the model's predictions if the gene expression data is not as smooth.
553 While these findings could alternatively suggest that neighboring patches may not be as
554 correlated as suspected, this may only hold true for a subset of genes. Increasing graph
555 convolution layers may result in optimal performance for genes, which rely on higher-order
556 dependencies between tissue regions; however, such genes may be outnumbered by genes
557 better suited for the Inception approach.

558
559 There were a few study limitations of note. Our validation scheme featured the use of held-out
560 slides. Generally, as two cases had tumor metastasis, whereas the other two did not have
561 concurrent metastasis, we believed held-out slides would have similar heterogeneity in
562 expression and morphology as the training/validation slides. Indeed, it is possible that tissue
563 expression/morphology existed outside of this range, differentially impacting the
564 GAT/transformer models designed to capture long-range spatial dependencies. As we had
565 manually selected capture areas, we did not expect slides to have exactly matching/analogous
566 architectural features; thus, the GAT/transformer model could have been unable to generalize
567 as it aims to integrate this higher-level information. There were four whole slide images for both
568 training and cross-validation, and while these provided over ten thousand patches in the training
569 set when taken individually, they provided limited opportunities for models to learn diverse
570 global contexts that transformer models would have benefitted from. These challenges could
571 have been ameliorated by pretraining the GAT/Transformer on a variety of colorectal cancer
572 tissue contexts, which does not explicitly require spatial omics data. We also acknowledge the
573 impact of evolving workflows for spatial resolution of transcriptomics information. Many
574 workflows rely on the prediction of tissue features from fresh or fresh frozen tissue. We utilized
575 formalin-fixed paraffin-embedded (FFPE) tissue slides. Only recently have deparaffinization and
576 assay workflows been developed for FFPE. As many of these specimen processing workflows
577 are still under development, manual staining and imaging could have both introduced batch
578 effects and impacted tissue quality. For instance, while a plethora of data preprocessing
579 workflows offer capabilities to combat batch effects through normalization, a robust
580 comparison of preprocessing workflows was outside of the study scope. Our group is keen to
581 adopt future iterations of the FFPE workflows. We expect that protocol updates for the FFPE
582 workflow and data collection will provide major improvements in specimen processing, data
583 quality, and resolution, improving prediction models. Enlarging the capture area and evaluating
584 complementary molecular assays (e.g., spatial proteomics) will improve the resolution and

585 scope of our findings. Although this work does not explicitly assess the tumor immune
586 microenvironment, the methodology explored here can help facilitate spatial analyses and will
587 be used to motivate future clinical findings. Future work will clearly demarcate these regions
588 (e.g., intratumoral, invasive margin, away from the tumor) for a more granular analysis that is
589 well-adjusted for potential confounders.

590
591

592 **5. Conclusions**

593 Tumor metastasis is heavily tied to poor prognostic outcomes and risk of recurrence.
594 Assessment of key niches at the primary site (e.g., tumor immune microenvironment) may
595 reveal histomorphological or biological factors relating to nodal involvement or distant
596 metastasis. In this work, we investigated the potential to infer spatially resolved transcriptomics
597 from the tissue histology of colorectal cancer patients through several sophisticated neural
598 network approaches. Our findings indicate that neural networks can be effectively employed in
599 this capacity and that selection of a neural network model could be informed by its relevance to
600 a molecular pathway resolved from histological features at different scales. Findings reaffirm
601 the role of the epithelial-to-mesenchymal transition as an important metastasis-related process.
602 In the future, with additional algorithmic fine-tuning, data curation, and standardization, there
603 are opportunities to generalize these findings to perform large-scale spatial molecular
604 assessments.

605
606

607 **Competing Interests**

608 None to disclose.

609
610

610 **Authors' Contributions**

611 The conception and design of the study were contributed by JL and LV. MF, EF, and CS
612 spearheaded study design, analysis, interpretation and initial manuscript drafting. All authors
613 contributed to writing and editing of the manuscript and all authors read and approved the final
614 manuscript.

615
616

616 **Acknowledgements**

617 We would like to thank Gabriel Brooks for his thoughtful discussion of the subject matter. This
618 work was supported by NIH grants R01CA216265, R01CA253976, and P20GM104416 to BC,
619 Dartmouth College Neukom Institute for Computational Science CompX awards to BC, JL and
620 LV, and DCC, DPLM Clinical Genomics and Advanced Technologies EDIT program. JL is
621 supported through NIH subawards P20GM104416 and P20GM130454. The funding bodies
622 above did not have any role in the study design, data collection, analysis and interpretation, or
623 writing of the manuscript.

624

625 **References**

- 626 1. Wong MC, Huang J, Lok V, et al. Differences in incidence and mortality trends of colorectal
627 cancer worldwide based on sex, age, and anatomic location. *Clin Gastroenterol Hepatol.*
628 2021;19(5):955-966.
- 629 2. Amin MB, Edge S, Greene F, et al., eds. *AJCC Cancer Staging Manual*. 8th ed. Springer
630 International Publishing; 2017. Accessed April 28, 2021.
631 <https://www.springer.com/gp/book/9783319406176>
- 632 3. Senthil M, Trisal V, Paz IB, Lai LL. Prediction of the Adequacy of Lymph Node Retrieval in
633 Colon Cancer by Hospital Type. *Arch Surg.* 2010;145(9):840-843.
634 doi:10.1001/archsurg.2010.182
- 635 4. Nearchou IP, Gwyther BM, Georgiakakis ECT, et al. Spatial immune profiling of the
636 colorectal tumor microenvironment predicts good outcome in stage II patients. *Npj Digit*
637 *Med.* 2020;3(1):1-10. doi:10.1038/s41746-020-0275-x
- 638 5. Uttam S, Stern AM, Sevinsky CJ, et al. Spatial domain analysis predicts risk of colorectal
639 cancer recurrence and infers associated tumor microenvironment networks. *Nat Commun.*
640 2020;11(1):3515. doi:10.1038/s41467-020-17083-x
- 641 6. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune
642 microenvironment (TIME) for effective therapy. *Nat Med.* 2018;24(5):541-550.
643 doi:10.1038/s41591-018-0014-x
- 644 7. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis
645 and therapeutic efficacy. *Nat Rev Cancer.* 2020;20(11):662-680. doi:10.1038/s41568-020-
646 0285-7
- 647 8. Wu Y, Cheng Y, Wang X, Fan J, Gao Q. Spatial omics: Navigating to the golden era of
648 cancer research. *Clin Transl Med.* 2022;12(1):e696. doi:10.1002/ctm2.696
- 649 9. Suwalska A, Zientek L, Polanska J, Marczyk M. Quantifying Spatial Heterogeneity of
650 Tumor-Infiltrating Lymphocytes to Predict Survival of Individual Cancer Patients. *J Pers*
651 *Med.* 2022;12(7):1113. doi:10.3390/jpm12071113
- 652 10. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature.* 2015;521(7553):436-444.
653 doi:10.1038/nature14539
- 654 11. He B, Bergensträhle L, Stenbeck L, et al. Integrating spatial gene expression and breast
655 tumour morphology via deep learning. *Nat Biomed Eng.* Published online June 22, 2020:1-8.
656 doi:10.1038/s41551-020-0578-x
- 657 12. Levy-Jurgenson A, Tekpli X, Kristensen VN, Yakhini Z. Spatial transcriptomics inferred
658 from pathology whole-slide images links tumor heterogeneity to survival in breast and lung
659 cancer. *Sci Rep.* 2020;10(1):18802. doi:10.1038/s41598-020-75708-z

- 660 13. Zeng Y, Wei Z, Yu W, et al. Spatial transcriptomics prediction from histology jointly
661 through Transformer and graph neural networks. *Brief Bioinform.* 2022;23(5):bbac297.
662 doi:10.1093/bib/bbac297
- 663 14. Pang M, Su K, Li M. Leveraging information in spatial transcriptomics to predict super-
664 resolution gene expression from histology images in tumors. Published online November 28,
665 2021:2021.11.28.470212. doi:10.1101/2021.11.28.470212
- 666 15. Levy JJ, Bobak CA, Nasir-Moin M, et al. Mixed Effects Machine Learning Models for
667 Colon Cancer Metastasis Prediction using Spatially Localized Immuno-Oncology Markers.
668 *Pac Symp Biocomput Pac Symp Biocomput.* 2022;27:175-186.
- 669 16. Svensson V, Teichmann SA, Stegle O. SpatialDE: identification of spatially variable genes.
670 *Nat Methods.* 2018;15(5):343-346. doi:10.1038/nmeth.4636
- 671 17. Szegedy C, Vanhoucke V, Ioffe S, Shlens J, Wojna Z. Rethinking the Inception Architecture
672 for Computer Vision. Published online December 11, 2015. doi:10.48550/arXiv.1512.00567
- 673 18. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An Image is Worth 16x16 Words:
674 Transformers for Image Recognition at Scale. In: ; 2020. Accessed August 28, 2021.
675 <https://openreview.net/forum?id=YicbFdNTTy>
- 676 19. Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list
677 enrichment analysis tool. *BMC Bioinformatics.* 2013;14(1):128. doi:10.1186/1471-2105-14-
678 128
- 679 20. McInnes L, Healy J, Saul N, Großberger L. UMAP: Uniform Manifold Approximation and
680 Projection. *J Open Source Softw.* 2018;3(29):861. doi:10.21105/joss.00861
- 681 21. McInnes L, Healy J, Astels S. hdbscan: Hierarchical density based clustering. *J Open Source*
682 *Softw.* 2017;2(11):205. doi:10.21105/joss.00205
- 683 22. Veen HJ van, Saul N, Eargle D, Mangham SW. Kepler Mapper: A flexible Python
684 implementation of the Mapper algorithm. *J Open Source Softw.* 2019;4(42):1315.
685 doi:10.21105/joss.01315
- 686 23. Tauzin G, Lupo U, Tunstall L, et al. giotto-tda: A Topological Data Analysis Toolkit for
687 Machine Learning and Data Exploration. *ArXiv200402551 Cs Math Stat.* Published online
688 April 6, 2020. Accessed July 23, 2020. <http://arxiv.org/abs/2004.02551>
- 689 24. Singh G, Mémoli F, Carlsson G. Topological Methods for the Analysis of High Dimensional
690 Data Sets and 3D Object Recognition. :10.
- 691 25. Zhu J, Sun S, Zhou X. SPARK-X: non-parametric modeling enables scalable and robust
692 detection of spatial expression patterns for large spatial transcriptomic studies. *Genome Biol.*
693 2021;22(1):184. doi:10.1186/s13059-021-02404-0

- 694 26. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin Gene (CDH1) Mutations
695 Predispose to Familial Gastric Cancer and Colorectal Cancer. *Hum Mol Genet.*
696 1999;8(4):607-610. doi:10.1093/hmg/8.4.607
- 697 27. SAWAZAKI S, OSHIMA T, SAKAMAKI K, et al. Clinical Significance of Tensin 4 Gene
698 Expression in Patients with Gastric Cancer. *In Vivo.* 2017;31(6):1065-1071.
699 doi:10.21873/invivo.11171
- 700 28. Pai SG, Carneiro BA, Mota JM, et al. Wnt/beta-catenin pathway: modulating anticancer
701 immune response. *J Hematol Oncol J Hematol Oncol.* 2017;10(1):101. doi:10.1186/s13045-
702 017-0471-6
- 703 29. Huang MS, Fu LH, Yan HC, et al. Proteomics and liquid biopsy characterization of human
704 EMT-related metastasis in colorectal cancer. *Front Oncol.* 2022;12:790096.
705 doi:10.3389/fonc.2022.790096
- 706 30. Li X, Li Z, Gu S, Zhao X. A pan-cancer analysis of collagen VI family on prognosis, tumor
707 microenvironment, and its potential therapeutic effect. *BMC Bioinformatics.* 2022;23:390.
708 doi:10.1186/s12859-022-04951-0
- 709 31. van Huizen NA, Coebergh van den Braak RRJ, Doukas M, Dekker LJM, IJzermans JNM,
710 Luijckx TM. Up-regulation of collagen proteins in colorectal liver metastasis compared with
711 normal liver tissue. *J Biol Chem.* 2019;294(1):281-289. doi:10.1074/jbc.RA118.005087

712
713
714

715 **Appendix**


716

717 **Supplementary Table 1.** Comparison of model performance for predicting
 718 dichotomized and log-transformed expression for genes across the whole
 719 transcriptome. These statistics are created by taking the median across all genes,
 720 reported for each held-out slide.
 721

Model	Slide	Classification		Regression	
		AUROC	AP	Spearman R	Pearson R
Inception-256	Overall	0.768	0.603	0.444	0.477
	A1	0.78	0.675	0.494	0.511
	B1	0.834	0.796	0.612	0.605
	C1	0.625	0.432	0.214	0.301
	D1	0.831	0.51	0.454	0.491
Inception-512	Overall	0.781	0.63	0.461	0.498
	A1	0.79	0.688	0.515	0.537
	B1	0.856	0.816	0.639	0.647
	C1	0.629	0.459	0.22	0.299
	D1	0.847	0.555	0.469	0.51
Inception-768	Overall	0.787	0.639	0.486	0.54
	A1	0.802	0.705	0.551	0.578
	B1	0.864	0.823	0.671	0.655
	C1	0.636	0.474	0.239	0.4
	D1	0.845	0.553	0.481	0.525
GAT-1	Overall	0.743	0.539	0.413	0.43
	A1	0.785	0.669	0.364	0.376
	B1	0.811	0.73	0.603	0.582
	C1	0.606	0.409	0.239	0.335
	D1	0.77	0.349	0.444	0.428
GAT-2	Overall	0.677	0.444	0.407	0.45
	A1	0.769	0.645	0.511	0.545
	B1	0.772	0.612	0.574	0.568
	C1	0.589	0.333	0.146	0.265
	D1	0.578	0.184	0.421	0.428
GAT-4	Overall	0.702	0.462	0.453	0.499
	A1	0.679	0.571	0.517	0.551
	B1	0.764	0.614	0.622	0.643
	C1	0.604	0.379	0.228	0.356
	D1	0.759	0.283	0.445	0.454
GAT-4-AXIN2	Overall	0.702	0.462	0.545	0.578
	A1	0.679	0.57	0.511	0.446
	B1	0.764	0.614	0.745	0.771
	C1	0.604	0.379	0.286	0.46
	D1	0.759	0.283	0.637	0.633
GAT-4-CDH1	Overall	0.800	0.707	0.546	0.571
	A1	0.826	0.747	0.468	0.478
	B1	0.858	0.791	0.753	0.741
	C1	0.648	0.462	0.31	0.425


	D1	0.867	0.827	0.652	0.64
GAT-1-ZINB	Overall	n/a	n/a	0.393	0.408
	A1	n/a	n/a	0.441	0.429
	B1	n/a	n/a	0.551	0.562
	C1	n/a	n/a	0.15	0.19
	D1	n/a	n/a	0.429	0.449
GAT-4-ZINB	Overall	n/a	n/a	0.41	0.432
	A1	n/a	n/a	0.485	0.542
	B1	n/a	n/a	0.602	0.621
	C1	n/a	n/a	0.128	0.2
	D1	n/a	n/a	0.426	0.364
ViT-224	Overall	0.756	0.583	0.436	0.454
	A1	0.768	0.644	0.511	0.506
	B1	0.826	0.762	0.601	0.567
	C1	0.604	0.413	0.177	0.255
	D1	0.827	0.513	0.455	0.487
ViT-384	Overall	0.765	0.601	0.446	0.468
	A1	0.794	0.678	0.513	0.521
	B1	0.836	0.788	0.612	0.583
	C1	0.606	0.406	0.213	0.307
	D1	0.823	0.530	0.446	0.462

722



723
724
725
726

Supplementary Figure 1: Scatterplot depicting gene-specific AUCs for GAT and Inception-768 for slides: A) A1; B) B1; C) C1; D) D1



727
728 **Supplementary Figure 2: Scatterplot depicting gene-specific AUCs for Inception-256**
729 **and Inception-768 for slides: A) A1; B) B1; C) C1; D) D1, E) Overall**

730
731
732 **Supplementary Table 2: Enrichr pathway results for genes found to be accurately**
733 **predicted from the tissue histology via the Inception and GAT approaches; pathways**
734 **were filtered based on tissue specificity**


Term	Overlap	Inception		GAT	
		Adjusted P-value	Term	Overlap	Adjusted P-value
EPCAM in Cancer Cell Motility and Proliferation	9/36	2.79e-07	Proteins with Altered Expression in Cancer Metastases	9/106	1.22e-03
Proteins with Altered Expression in Cancer Metastases	11/106	2.82e-05	Desmosome Assembly	4/18	4.56e-03
Epithelial Cell in the Saliva Formation	5/13	7.15e-05	Corneodesmosomes in Atopic Dermatitis	4/19	5.15e-03
Androgens in Sebocyte Maturation	8/65	1.69e-04	Proteins with Altered Expression in Cancer Metabolic Reprogramming	7/85	5.50e-03
Proteins Involved in Ulcerative Colitis	11/141	1.69e-04	WNT in Epithelial to Mesenchymal Transition in Cancer	5/43	8.09e-03
Desmosome Assembly	5/18	1.70e-04	Metabolic Effects of Oncogenes and Tumor Suppressor in Cancer Cells	6/68	8.09e-03
Corneodesmosomes in Atopic Dermatitis	5/19	2.03e-04	Proteins Involved in Myocardial Ischemia	11/252	1.18e-02
Proteins Involved in Colorectal Neoplasms	9/99	2.35e-04	Desmosome Dysfunction in Cardiomyocyte	3/12	1.26e-02
WNT in Epithelial to Mesenchymal Transition in Cancer	6/43	5.66e-04	RAGE/AGER and S100 Proteins in Cardiovascular Injury	4/30	1.56e-02
Acinar Cells in the Saliva Formation	4/13	5.66e-04	Desmosomes Role in Dilated Cardiomyopathy	3/15	2.31e-02
Epithelial to Mesenchymal Transition in Cancer: Overview	8/90	5.85e-04	Epithelial to Mesenchymal Transition in Cancer: Overview	6/90	2.58e-02
Metastatic Colorectal Cancer	9/121	7.01e-04	Proteins Involved in Atherosclerosis	9/200	2.58e-02
Proteins with Altered Expression in Cancer Metabolic Reprogramming	7/85	2.43e-03	Cetuximab Resistance in Colorectal Cancer	5/64	3.05e-02
Telogen Maintenance in Androgenic Alopecia	4/23	4.15e-03	Proteins Involved in Colorectal Neoplasms	6/99	3.41e-02
Cancer Cells Inhibit Adipocyte Differentiation	4/27	6.43e-03	Glycolysis Activation in Cancer (Warburg Effect)	4/40	3.41e-02
TGFβ Family in Epithelial to Mesenchymal Transition in Cancer	6/80	8.55e-03			

Fatty Acid Synthase (FASN) Signaling	3/16	1.52e-02
WNT Signaling Activation by Blocking of Tumor Suppressors	4/36	1.57e-02
HPV Infection and Cancer	5/65	1.80e-02
Androgens in Adipocyte Activation	3/18	1.80e-02
Glycolysis Activation in Cancer (Warburg Effect)	4/40	1.97e-02
Metabolic Effects of Oncogenes and Tumor Suppressor in Cancer Cells	5/68	1.98e-02
Proteins Involved in HPV Infection	3/19	1.98e-02
CDH1 Down regulation Promotes Cancer Cell Migration and Metastases	4/44	2.45e-02
Androgen Deficiency in Male Obesity	3/24	3.31e-02
Sialophorin -> CTNNB/MYC/TP53 Signaling	3/25	3.60e-02
mRNA Degradation	3/26	3.91e-02
WNT Canonical Signaling Activation in Cancer	3/27	4.16e-02
Proteins Involved in Arterial Hypertension	9/255	4.30e-02
Hyaluronic Acid, CD44 and HMMR in Cancer Cell Invasion and Survival	4/56	4.35e-02
Estrogen Deficiency in Female Obesity	2/9	4.35e-02
Adipocyte Hypertrophy and Hyperplasia	3/29	4.50e-02
Proteins Involved in Hepatocellular Carcinoma	6/130	4.74e-02
Adherens Junction Assembly (Cadherins)	3/30	4.83e-02
Proteins with Altered Expression in Cancer-Associated Sustaining of Proliferative Signaling	7/175	5.00e-02

735


736

737




738
739
740
741
742
743

Supplementary Figure 3: Boxenplots illustrating the predictive accuracy of Inceptionv3 (AUC, y-axis) across genes, separated by the genes' Automatic Expression Histology groups (colors, x-axis); gathered from validation slides held-out of the training/validation set. Different groups were assigned for each slide. A-D) correspond to slides A1-D1 respectively



744

745 **Supplementary Figure 4: Spatial expression patterns for select AEH groups for slides:**
 746 **A) A1; B) B1;** genes from the first featured AEH group for each slide were predicted with
 747 low accuracy; genes from the final two AEH groups were predicted with high accuracy
 748



749 **Supplementary Figure 5: Spatial expression patterns for select AEH groups for slides:**
 750 **A) C1; B) D1;** genes from the first featured AEH group for each slide were predicted with
 751 low accuracy; genes from the final two AEH groups were predicted with high accuracy
 752
 753

754 **Supplementary Table 3: Genes differentially spatially autocorrelated between**
 755 **METS/No-METS**

Ground Truth			
Randomly Selected Genes	Pathways	Overlap	Adj. P-Value
STXBP3	Epithelial Mesenchymal Transition	17/200	2.53e-09
IMPAD1	Coagulation	11/138	0.000006432
ING1	TGF-beta Signaling	11/200	0.002024
YY1AP1	Myogenesis	11/200	0.0001214
IGFBP4	Apical Junction	10/200	0.0001214
ACO1	Hypoxia	5/54	0.0005478
ID3	Cholesterol Homeostasis	6/144	0.02979
PTAR1	UV Response Dn	7/199	0.02582
SYNM	UV Response Up	7/200	0.0286
SPRY2	IL-2/STAT5 Signaling	7/200	0.02582
RABL3	Estrogen Response Late	6/158	0.02582
N4BP2L2	p53 Pathway	4/74	0.02582

Inception

Randomly Selected Genes	Pathways	Overlap	Adj. P-Value
DPYSL3	Epithelial Mesenchymal Transition	9/200	3.41e-13
CALD1	TGF-beta Signaling	3/138	0.004267
G0S2	Coagulation	3/200	0.001833
IGHG1	TNF-alpha Signaling via NF-kB	2/54	0.003624
LIMS2	Angiogenesis	2/200	0.05432
COL6A2	Xenobiotic Metabolism	2/200	0.02452
C1S	Hypoxia	2/200	0.02452
SERPINF1	Myogenesis	2/200	0.02452
FOSB	Complement	2/200	0.02452
SORBS1	Inflammatory Response	1/36	0.02452
WIPF1	IL-6/JAK/STAT3 Signaling	1/87	0.1169
PCOLCE	Interferon Alpha Response	1/97	0.119

GAT

Randomly Selected Genes	Pathways	Overlap	Adj. P-Value
ACTA2	Epithelial Mesenchymal Transition	18/200	1.85e-27
COL5A2	Angiogenesis	4/36	0.000002955
COL3A1	Myogenesis	5/200	0.00009592
COL12A1	Glycolysis	3/200	0.01585
GREM1	Apical Junction	3/200	0.01585
CDH11	Hedgehog Signaling	2/138	0.1196
SPARCL1	Apical Surface	2/144	0.1321
CRYAB	Coagulation	2/200	0.06564
POSTN	UV Response Dn	2/200	0.06564
TPM2	TGF-beta Signaling	1/36	0.1475
DES	Hypoxia	1/44	0.09354
DCN	Adipogenesis	1/54	0.09354

756

757

758